Valuation: CEL-SCI Corporation

Market Cap 29.9M 26.3M 24.87M 22.56M 42.36M 2.87B 42.61M 298M 115M 1.46B 112M 110M 4.71B P/E 2026 *
-0.55x
P/E 2027 * -0.27x
Enterprise Value 24.35M 21.41M 20.25M 18.37M 34.49M 2.34B 34.69M 242M 93.63M 1.19B 91.41M 89.43M 3.83B EV / Sales 2026 *
-
EV / Sales 2027 * 4.11x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+1.80%
1 week+1.80%
Current month+4.94%
1 month+8.97%
3 months+53.15%
6 months-46.88%
Current year-67.68%
1 week 1.66
Extreme 1.665
1.76
1 month 1.46
Extreme 1.46
1.76
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
10.83
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
384.64
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 31/12/1994
Director of Finance/CFO 75 12/11/2024
Chief Tech/Sci/R&D Officer - 30/04/2024
Director TitleAgeSince
Director/Board Member 67 31/12/1994
Director/Board Member 73 21/06/2015
Chairman 69 07/07/2024
Date Insider Type Main position Quantity % Market Cap. Importance
25/08/26 Buy

Chief Executive Officer

100,000 0.5722%
14/08/26 Free

Chief Financial Officer

225,000 1.2874%
14/08/26 Free

Director

110,000 0.6294%
Change 5-day change 1-year change 3-year change Capi.($)
+1.80%+1.80%-81.01%-95.32% 29.9M
-0.37%-3.67%+57.21%+87.75% 71.81B
-0.07%-2.70%+37.74%+86.90% 60.06B
-0.37%+0.66%+33.84%+16.10% 27.93B
-0.14%-2.75%-14.13%+356.79% 25.7B
+0.57%+1.10%+1.02%-2.89% 24.89B
+1.10%+1.86%+25.07%-7.59% 20.92B
-1.70%+0.43%+150.24%+323.16% 15.04B
+0.36%+2.01%+49.51%+160.70% 14.46B
+5.01%-2.86%-3.91%+521.67% 13.87B
Average +0.54%-1.19%+25.56%+144.73% 27.47B
Weighted average by Cap. +0.09%-1.91%+37.95%+128.59%

Financials

2026 *2027 *
Net sales - 5.97M 5.25M 4.97M 4.5M 8.46M 573M 8.51M 59.47M 22.97M 293M 22.42M 21.94M 940M
Net income -25.08M -22.06M -20.86M -18.92M -35.54M -2.41B -35.74M -250M -96.47M -1.23B -94.18M -92.14M -3.95B -29.51M -25.96M -24.55M -22.26M -41.81M -2.83B -42.05M -294M -114M -1.45B -111M -108M -4.65B
Net Debt -5.55M -4.88M -4.62M -4.19M -7.87M -533M -7.91M -55.31M -21.36M -272M -20.85M -20.4M -874M -5.34M -4.7M -4.44M -4.03M -7.56M -512M -7.61M -53.16M -20.53M -262M -20.04M -19.61M -840M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
28/09/26 US$1.700 +1.80% 126,230
25/09/26 US$1.670 -2.91% 36,410
24/09/26 US$1.720 +2.38% 56,130
23/09/26 US$1.680 -1.18% 171,391
22/09/26 US$1.700 +1.80% 133,848
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.700USD
Average target price
12.50USD
Spread / Average Target
+635.29%

Annual profits - Rate of surprise